search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


The acute effects of cannabis on the brain


- candidate number3303
- NTR NumberNTR1318
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR19-mei-2008
- Secondary IDs200801 
- Public TitleThe acute effects of cannabis on the brain
- Scientific TitleCannabis as a cause of psychosis: an ecogenetic study linking cannabis-induced dopamine response to psychotic mechanisms and experiences
- ACRONYMCannabis as a cause of psychosis: an ecogenetic study linking cannabis-induced dopamine response to psychotic mechanisms and experiences
- hypothesis1. Cannabis use increases striatal dopamine release
2. Striatal dopamine release predicts cannabis induced-psychotic experiences
3. Cannabis-induced striatal dopamine response varies as a function of genetic risk for psychosis
- Healt Condition(s) or Problem(s) studiedPsychosis, Cannabis, Tetrahydrocannabinol (THC), Dopamine
- Inclusion criteria1. Aged between 18 and 50
2. Life-time use of cannabis without having experienced negative effects (e.g. bad trip, toxic psychosis)
3. BMI between 18.5 and 27
4. Having signed informed consent
5. Clinical diagnosis of non-affective schizophrenia or psychotic disorder according to DSM-IV
(REFERS ONLY TO PATIENTS)
- Exclusion criteria1. Head trauma
2. Respiratory, cardiovascular, neurological disease, severe renal or liver dysfunction
3. Alcohol use in excess of 5 units per day
4. Weekly use of illicit drugs (other than cannabis)
5. Current use of antipsychotic medication or medication known to interfere with the CB1 receptor (e.g. rimonabant)
6. Pregnancy and breastfeeding
7. Personal or family history of psychosis
(REFERS ONLY TO HEALTHY CONTROLS)
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupCrossover
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jun-2008
- planned closingdate30-mei-2011
- Target number of participants30
- InterventionsExposure to delta-9-tetrahydrocannabinol (THC, psychoactive component of cannabis, 8 mg) and placebo
- Primary outcomeA. Striatal dopamine response after THC and placebo, as measured with PET and [18F]fallypride
B. Psychotic experiences after THC and placebo, as measured with i) novel computer-assisted tasks and ii)clinical interviews
- Secondary outcomeC. Influence of genetic variation
- TimepointsOne timepoint (t1)
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES Rebecca Kuepper
- CONTACT for SCIENTIFIC QUERIES Rebecca Kuepper
- Sponsor/Initiator University Maastricht (UM)
- Funding
(Source(s) of Monetary or Material Support)
University Maastricht (UM), NWO
- PublicationsN/A
- Brief summaryThe study aims at elucidating the biological mechanism behind the cannabis-psychosis relationship. By using PET and [18F]fallypride, the striatal dopamine response is measured after THC or placebo exposure. Novel computer-assisted tasks as well as clinical interviewing are used to assess psychotic experiences behaviorally.
- Main changes (audit trail)
- RECORD19-mei-2008 - 23-jul-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl